Archive by category | Partnering / Licensing

North-South Dealing

North-South Dealing

Entrepreneurial life sciences companies have set their sights on overseas markets and have formed international partnerships to gain access to distribution channels and insight on product specifications, registration, and user preferences. I estimate that this “global health” market place is between $250-300 billion in annual sales, using a 2009 pharmaceutical sales forecast that put 14% of the total of $820 billion resulting from the emerging economies of China, Brazil, India, South Korea, Mexico, Turkey, and Russia (2009 Forecast), and so about 17% ($147 billion) occurred in the rest of world including those countries with few resources in health care. Applying the same ratio to a world diagnostics market of $44 billion, I add another $14 billion, giving a approximate non-US/EU/Japan global health pharma/diagnostics products market of $276 billion.  Read more

Going Nonexclusive

Going Nonexclusive

Start up companies face a tough go- converting a new technology into saleable products on minimal funding- and those aiming at products for global health (or any health care products for sale outside the major market countries) have even a harder challenge by swimming against the conventional wisdom that a highly-priced, reimbursable product is the only way to profitability. For start-ups, time is money and the shorter time to a product prototype, the more likely is revenue and survival. To fund prototype development, most patch together funding from government (or very rarely, foundation) grants and private sources while trying to convince a major, established company that it wants access to the technology and/or the possibly-resulting products.  Read more

New Bioentrepreneur article

New Bioentrepreneur article

We’ve posted a new article, Shape Shifting, to the Bioentrepreneur site. The piece examines how to mold a company’s pipeline and opportunities, making it most attractive for partnering or buyout. It was written Bob Baltera, CEO of Amira (at the time), and the title refers to the necessity of changing the shape of a company as it progresses.  Read more

Czech Republic´s International Cooperation

Czech Republic´s International Cooperation

Few in the healthcare industry have not heard about Gilead Sciences’ success against HIV/AIDS and hepatitis B. Viread and Hepsera, the two flagship drugs for treating these conditions, were first conceived by Czech scientists in the Prague-based Institute of Organic Chemistry and Biochemistry, led by professor Antonin Holy. They discovered tenofovir disoproxil fumarate, the active ingredient in Viread, which is used to treat HIV/AIDS. Likewise, the hepatitis B drug Hepsera produced by Gilead Sciences is based on a compound discovered in Prof. Holy’s laboratory in Prague. As a result of previous cooperation between the institute and Gilead, Holy signed a contract with Gilead, offering his discoveries in basic research. Gilead took his work and further developed it.  Read more

India ‘fixated’?

India ‘fixated’?

I recently read this article, which suggests that collaborations between India and Brazil are being held back because India prefers to partner with others – namely countries in the West. It prompted some thinking on my part.  Read more

Russia-India Biotech Network

Russia-India Biotech Network

In order to improve and encourage bilateral trade between India and Russia, the two countries have signed the Russia-India Biotech Network (RIBN) agreement to enhance collaboration in the biotechnology sector. The RIBN is jointly developed by the Federation of Asian Biotech Associations (FABA) and Russian Biotech Association. This development holds immense significance for Indian small and medium enterprises (SMEs) in the biotech sectors, which are likely to be encouraged by these developments to partner with Russian biotech companies for further business expansion. RIBN will be a dedicated online platform to effectively facilitate collaboration between the Russian and Indian biotech communities.  Read more

Demystifying China: Start up

Demystifying China: Start up

People read a lot about China these days. There is the booming economy, maintaining over 8% GDP growth in the midst of a slow global recovery. The Chinese pharmaceutical market is projected to climb into the world’s top three in 2011. The healthcare reform plan is supposed to inject US$128 billion into the healthcare system between 2009 and 2011, and has already helped double pharmaceutical sales one and a half years into the plan. We also hear trendy phrases such as the globalization of drug development, the new paradigm of drug development, FIPnet (Fully Integrated Pharmaceutical Network), superpharma, virtual biotech…and they all seem to be related to China one way or another.  Read more